Common chronic diseases represent the greatest driver of rising healthcare costs, as well as
declining function, independence, and quality of life. Geroscience‐guided approaches seek …

Cardiovascular diseases (CVDs) are serious public health issues and are responsible for
nearly one-third of global deaths. Mitochondrial dysfunction is accountable for the …

Cardiac aging is evident by a reduction in function which subsequently contributes to heart
failure. The metabolic microenvironment has been identified as a hallmark of malignancy …

Abstract Sodium-glucose cotransporter 2 (SGLT2) inhibitors have evident cardiovascular
benefits in patients with type 2 diabetes with or at high risk for atherosclerotic cardiovascular …

Background It has been proven that sodium-glucose co-transporter 2 inhibitors (SGLT2is)
improve the prognosis of patients with heart failure, independent of the presence of diabetes …

The reduction-oxidation (redox) system consists of the coupling and coordination of various
electron gradients that are generated thanks to serial reduction-oxidation enzymatic …

Diabetes mellitus and related disorders significantly contribute to morbidity and mortality
worldwide. Despite the advances in the current therapeutic methods, further development of …

Parkinson's disease (PD) is the second most common neurodegenerative disease after
Alzheimer's disease affecting more than 1% of the population over 65 years old. The …

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a class of newly introduced
antidiabetic drugs with potent hypoglycemic effects. Recent evidence suggests that these …

The pathogenesis of diabetes is accompanied by increased levels of inflammatory factors,
also known as “metabolic inflammation”, which runs through the whole process of the …